var data={"title":"Polyethylene glycol electrolyte solution: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polyethylene glycol electrolyte solution: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6798?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-drug-information\" class=\"drug drug_general\">see &quot;Polyethylene glycol electrolyte solution: Drug information&quot;</a> and <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polyethylene glycol electrolyte solution: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211122\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Colyte;</li>\n      <li>GaviLyte-C;</li>\n      <li>GaviLyte-G;</li>\n      <li>GaviLyte-N;</li>\n      <li>GoLYTELY;</li>\n      <li>MoviPrep;</li>\n      <li>NuLYTELY;</li>\n      <li>TriLyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211123\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Colyte;</li>\n      <li>Klean-Prep;</li>\n      <li>PegLyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061227\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Laxative, Bowel Evacuant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Laxative, Osmotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061220\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-drug-information\" class=\"drug drug_general\">see &quot;Polyethylene glycol electrolyte solution: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Bowel cleansing</b> (to prevent excessive fluid and electrolyte changes, use only products containing supplemental electrolytes for bowel cleansing): Patient should fast at least 2 hours (preferably 3 to 4 hours) prior to ingestion: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants &ge;6 months, Children, and Adolescents: Oral, nasogastric: GaviLyte-N, NuLYTELY, and TriLyte: 25 mL/kg/hour until rectal effluent is clear (usually in ~4 hours). One study used 40 mL/kg/hour intermittently by mouth or continuously by nasogastric drip in patients &ge;18 months (Sondheimer 1991). Although not FDA approved for pediatric patients, other preparations have been used in pediatric studies: Colyte, GoLYTELY (Sondheimer 1991; Tuggle 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Fecal impaction; slow disimpaction:</b> Limited data available: Children&gt; 2 years and Adolescents: Oral, Nasogastric: 20 mL/kg/hour up to a maximum dose of 1 L/hour for 4 hours per day for 2 days was evaluated in a study comparing polyethylene glycol with electrolytes lavage (n=19, mean age: 6.44 &plusmn; 2.36 years) to mineral oil (n=17, mean age: 6.88 &plusmn; 3.26 years)  (Tolia 1993) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Toxic ingestion</b> (AACT 2004): Nasogastric:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants &ge;9 months and Children &lt;6 years: 500 mL/hour until rectal effluent is clear </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;6 years: 1,000 mL/hour until rectal effluent is clear </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents: 1,500 to 2,000 mL/hour until rectal effluent is clear </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> Continue treatment at least until the rectal effluent is clear; treatment duration may be extended based on corroborative evidence of continued presence of poisons in the GI tract as determined by radiographic means or the presence of the poison in the effluent. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Bowel cleansing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 240 mL (8 oz) every 10 minutes until 4 L are consumed or the rectal effluent is clear; rapid drinking of each portion is preferred to drinking small amounts continuously</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Nasogastric: 20 to 30 mL/minute until 4 L are administered or the rectal effluent is clear</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MoviPrep: Oral: Administer 2 L total with an additional 1 L of clear fluid prior to colonoscopy as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Split dose (2-day regimen) (preferred method): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 1: Evening before colonoscopy (10 to 12 hours before dose 2): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 480 mL (16 oz) of clear liquid and consume prior to going to bed.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 2: On the morning of the colonoscopy (beginning at least 3.5 hours prior to procedure): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 480 mL (16 oz) of clear liquid and consume at least 2 hours before the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Evening only dose (1-day regimen) (alternate method): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 1: Evening before colonoscopy (at least 3.5 hours before bedtime): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 2: ~90 minutes after starting dose 1: 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 1 L (32 oz) of clear liquid and consume all of the liquid prior to going to bed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (not studied). Use with caution due to risks of fluid and electrolyte abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b>  There are no dosage adjustments provided in manufacturer&rsquo;s labeling (not studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211104\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, for solution, oral: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL); PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL); PEG 3350 240 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL); PEG 3350 420 g,  sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Colyte: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g (3785 mL) [supplied with cherry, lemon lime, and orange flavor packs]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Colyte: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLyte-C: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with lemon flavor packet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLyte-G: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [supplied with lemon flavor packet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLyte-N: PEG 3350 420 g,  sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with lemon flavor packet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoLYTELY: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g per packet (1s) [regular flavor; makes 1 gallon of solution after mixing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoLYTELY: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [regular and pineapple flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MoviPrep: Pouch A: PEG 3350 100g, sodium sulfate 7.5 g, sodium chloride 2.69 g, potassium chloride 1.02 g; Pouch B: Ascorbic acid 4.7 g, sodium ascorbate 5.9 g (1000 mL) [contains phenylalanine 131 mg/treatment; lemon flavor; packaged with 2 of Pouch A and 2 of Pouch B in carton and a disposable reconstitution container]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NuLYTELY: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, lemon-lime, orange, and pineapple flavor packs]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TriLyte: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs] </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211090\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12808915\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">GoLYTELY: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370635.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5Wd8Hdxs7P4TWhlGyV2cRdIw==&amp;TOPIC_ID=12715\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370635.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">MoviPrep: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV689pCzBsfS0zDVXju3jjAXVA==&amp;TOPIC_ID=12715\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">NuLYTELY: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370636.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WyTYpqPI+HCyVv3fluBWY+A==&amp;TOPIC_ID=12715\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370636.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061230\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: For bowel cleansing, no solid foods for 2 to 4 hours prior to initiation of therapy; rapid drinking is preferred to drinking small amounts continuously; chilled solution often more palatable, but not recommended for infants; refrigerate reconstituted solution when not in use; do not add ingredients as flavorings before use; discard any unused portion. The  solution may be administered via nasogastric tube for bowel cleansing or whole bowel irrigation in patients who are unwilling or unable to drink the solution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211119\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte: Prior to reconstitution, store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Refrigerate reconstituted solution. Use within 48 hours of preparation; discard any unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">MoviPrep: Prior to reconstitution, store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).  Refrigerate reconstituted solution in an upright position. Use within 24 hours of preparation; discard any unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061229\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Bowel cleansing prior to GI procedure (GaviLyte-N, NuLYTELY, Trilyte: FDA approved in ages &ge;6 months and adults; MoviPrep: FDA approved in ages &ge;18 and adults; Colyte, GaviLyte-C, GaviLyte-G: FDA approved in adults); has also been used for whole bowel irrigation after toxic ingestions and for treatment of fecal impaction </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211145\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoLYTELY may be confused with NuLYTELY </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TriLyte may be confused with TriLipix</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Polyethylene glycol 3350 may be confused with polyethylene glycol 4000 [international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211144\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, headache, malaise, rigors, sleep disorder </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Increased thirst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distention, abdominal pain, anorectal pain, bloating, dyspepsia, hunger, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, angioedema, aspiration, asystole (older adults &gt;60 years), chest tightness, esophageal perforation (older adults &gt;60 years), hypersensitivity reaction, ischemic colitis, Mallory-Weiss syndrome (older adults &gt;60 years), pulmonary edema (older adults &gt;60 years), rhinorrhea, seizure, shock, tightness in chest and throat, upper gastrointestinal hemorrhage (older adults &gt;60 years), urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211110\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to polyethylene glycol or any component of the formulation; ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211094\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Serious arrhythmias have been reported (rarely) with the use of ionic osmotic laxative products. Use with caution in patients who may be at risk of  cardiac arrhythmias (eg, patients with a history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid and electrolyte abnormalities: Fluid and electrolyte disturbances can lead to arrhythmias, seizures, and renal impairment. Advise patients to maintain adequate hydration before, during, and after treatment. If patient becomes dehydrated or experiences significant vomiting after treatment, consider post-colonoscopy lab tests (electrolytes, creatinine, and BUN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ischemic colitis: Cases of ischemic colitis have been reported; concomitant use of stimulant laxatives may increase the risk and is not recommended.  The potential for mucosal aphthous ulcerations as a result of the bowel preparation should be considered, especially when evaluating colonoscopy results in patients with known or suspected inflammatory bowel disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Generalized tonic-clonic seizures and/or loss of consciousness have occurred rarely in patients with no prior history of seizures. Seizures resolved with the correction of fluid and electrolyte abnormalities. Use with caution in patients with a history of seizures or who are at an increased risk of seizures (eg, concomitant administration of medications that lower the seizures threshold, patients withdrawing from alcohol or benzodiazepines) and in patients with known or suspected hyponatremia or low serum osmolality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment and/or in patients taking medications that may adversely affect renal function (eg, diuretics, NSAIDs, ACE inhibitors, ARBs). Patients with impaired renal function should be instructed to remain adequately hydrated; consider pre-dose and post-colonoscopy lab tests (electrolytes, creatinine, BUN) in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ulcerative colitis: Use with caution in patients with severe ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in patients &gt;60 years of age; serious adverse events have been reported (eg, asystole, esophageal perforation, chest infiltration following vomiting and aspiration, Mallory-Weiss tear with GI bleeding, pulmonary edema with sudden dyspnea).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use in patients &lt;2 years of age may result in hypoglycemia, dehydration, and hypokalemia; use with caution and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; MoviPrep: Use with caution in patients with G6PD deficiency (especially patients with an active infection, history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions) due to the presence of sodium ascorbate and ascorbic acid in the formulation. Contains phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction or perforation (nausea, vomiting, abdominal pain or distension) prior to use; if a patient develops severe bloating, distention or abdominal pain during administration, slow the rate of administration or temporarily discontinue use until the symptoms subside. Correct electrolyte abnormalities in patients prior to use. No additional ingredients or flavors (other than the flavor packets provided) should be added to the polyethylene glycol-electrolyte solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27778495\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">The effects of long-term use or large doses of polyethylene glycol in children are unknown. The FDA has received reports of metabolic acidosis (with and without anion gap) and neuropsychiatric events in children taking polyethylene glycol products; however, direct causality with the drug has not been established. Neuropsychiatric adverse events reported may include seizures, tremors, tics, headache, anxiety, lethargy, sedation, aggression, rages, obsessive-compulsive behaviors (including repetitive chewing and sucking), paranoia, and mood swings. Studies are underway to define the metabolic processes and pathways of polyethylene glycol (and any metabolites) in pediatric patients and to determine gastrointestinal absorption properties if any (FDA 2013). As of 2014, the FDA decided no action was necessary based upon available data (FDA 2014). Monitor pediatric patients closely for signs of metabolic acidosis or neuropsychiatric changes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299900\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222413\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12715&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211100\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211113\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Information related to the use of polyethylene glycol-electrolyte solution in pregnancy is limited (Neri, 2004). Colonoscopy in pregnant women is generally reserved for strong indications or life-threatening emergencies; until additional safety data for polyethylene glycol-electrolyte solution is available, other agents may be preferred for this purpose (Siddiqui, 2006; Wexner, 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061226\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Electrolytes, BUN, serum glucose, urine osmolality; children &lt;2 years of age should be monitored for hypoglycemia, dehydration, hypokalemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211093\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces catharsis by strong electrolyte and osmotic effects</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211109\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Onset of effect: Oral: ~1 hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16319576\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Concentrations for reconstituted solutions:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When prepared as recommended by the manufacturer, the solutions will contain: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CoLyte, GaviLyte-C: When dissolved in sufficient water to make 4,000 mL, the final solution contains PEG-3350 60 g/L, sodium 125 mEq/L, sulfate 80 mEql/L, chloride 35 mEql/L, bicarbonate 20 mEq/L, and potassium 10 mEq/L </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GaviLyte-G, GoLYTELY: When dissolved in sufficient water to make 4,000 mL, the final solution contains PEG-3350 59 g/L, sodium 125 mEq/L, sulfate 40 mEq/L, chloride 35 mEq/L, bicarbonate 20 mEq/L, and potassium 10 mEq/L </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GaviLyte-N, NuLYTELY, TriLyte: When dissolved in sufficient water to make 4,000 mL, the final solution contains PEG-3350 105 g/L, sodium 65 mEq/L, chloride 53 mEq/L, bicarbonate 17 mEq/L, and potassium 5 mEq/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4589209\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Colyte with Flavor Packs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 g (4000 mL): $68.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GaviLyte-C Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 g (4000 mL): $19.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GaviLyte-G Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">236 g (4000 mL): $21.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GaviLyte-N with Flavor Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Golytely Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">227.1 g (1): $15.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">236 g (4000 mL): $23.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (MoviPrep Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 g (1): $119.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nulytely with Flavor Packs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $32.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (PEG 3350-KCl-Na Bicarb-NaCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $22.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (TriLyte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $28.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29044095\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Barex (AR);</li>\n      <li>Cleargol (AU);</li>\n      <li>Coloclean (IN);</li>\n      <li>Colofort (BE, NL);</li>\n      <li>Colonsoft (FI);</li>\n      <li>Colopeg (IN);</li>\n      <li>CosmoCol (GB);</li>\n      <li>Delcoprep (DE);</li>\n      <li>Endofalk (BE, CL, DK, FI, NO, PT, RU, SE, UA);</li>\n      <li>Endopeg (IN);</li>\n      <li>Gangiden (DK);</li>\n      <li>Glycoprep (AU, NZ);</li>\n      <li>Golytely (TR);</li>\n      <li>GoLytely (ZA);</li>\n      <li>Icolon (IN);</li>\n      <li>Iscolan (CH);</li>\n      <li>Klean Prep (AT);</li>\n      <li>Klean-Prep (BE, CH, DE, ES, FR, GB, GR, HK, IT, LB, MT, NL, NZ, PT, QA, SG, ZA);</li>\n      <li>Laxacon (AU);</li>\n      <li>Laxido (FI, SE);</li>\n      <li>Macrovic (AU);</li>\n      <li>Meroken New (IL);</li>\n      <li>Molaxole (AT, CH, CY, EE, ES, GR, HU, IT, NL, NO, PT, SE, SK, TR);</li>\n      <li>Movicol (AE, AT, BE, CN, DE, DK, ES, FI, FR, GB, IN, IS, IT, JO, KW, LB, LK, MT, NO, NZ, PT, QA, SE, SG, VN, ZA);</li>\n      <li>Moviprep (AU, BB, CZ, EE, GB, HR, IS, JO, KW, LB, LT, LU, MT, NO, NZ, SA, SI);</li>\n      <li>Movyprep (UA);</li>\n      <li>Moxalole (DK, FI, FR, PL);</li>\n      <li>NuLytely (MX);</li>\n      <li>Oralav (DE);</li>\n      <li>Osmolax (AT);</li>\n      <li>Peglyte (SG);</li>\n      <li>ShuTaiQing (CN);</li>\n      <li>Transipeg (BE, CH, FR, RU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists, &quot;Position Paper: Whole Bowel Irrigation,&quot; <i>J Toxicol Clin Toxicol</i>, 2004, 42(6):843-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/15533024/pubmed\" target=\"_blank\" id=\"15533024\">15533024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). Drug safety Oversight Board Meeting, June 18, 2019. Available at <a href=\"http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm171059.htm\" target=\"_blank\">http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm171059.htm</a>. Last accessed January 20, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS) between october - december 2011. Available at <a href=\"http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm295585.htm\" target=\"_blank\">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm295585.htm</a>. Last accessed January 20, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neri I, Blasi I, Castro P, et al, &quot;Polyethylene Glycol Electrolyte Solution (Isocolan) for Constipation During  Pregnancy: An Observational Open-Label Study,&quot; <i>J Midwifery Womens Health</i>, 2004 , 49(4):355-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/15236717/pubmed\" target=\"_blank\" id=\"15236717\">15236717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siddiqui U and Denise Proctor D, &quot;Flexible Sigmoidoscopy and Colonoscopy During Pregnancy,&quot; <i>Gastrointest Endosc Clin N Am</i>, 2006, 16(1):59-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/16546023/pubmed\" target=\"_blank\" id=\"16546023\">16546023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sondheimer JM, Sokol RJ, Taylor SF, et al, &ldquo;Safety, Efficacy and Tolerance of Intestinal Lavage in Pediatric Patients Undergoing Diagnostic Colonoscopy,&rdquo; <i>J Pediatr</i>, 1991, 119(1):148-52. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/2066847/pubmed\" target=\"_blank\" id=\"2066847\">2066847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. <i>J Pediatr Gastroenterol Nutr</i>. 2014;58(2):258-274.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/24345831 /pubmed\" target=\"_blank\" id=\"24345831 \">24345831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tolia V, Lin CH, Elitsur Y. A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children. <i>Aliment Pharmacol Ther</i>. 1993;7(5):523-529.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/8280820 /pubmed\" target=\"_blank\" id=\"8280820 \">8280820 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuggle DW, Hoelzer DJ, Tunell WP, et al, &ldquo;The Safety and Cost-Effectiveness of Polyethylene Glycol Electrolyte Solution Bowel: Preparation in Infants and Children,&rdquo; <i>J Pediatr Surg</i>, 1987, 22(6):513-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/311235/pubmed\" target=\"_blank\" id=\"311235\">311235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wexner SD, Beck DE, Baron TH, et al,  &ldquo;A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force from The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal and Endoscopy (ASGE) and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES),&rdquo; <i>Dis Colon Rectum</i>, 2006, 49(6):792-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-pediatric-drug-information/abstract-text/16649119/pubmed\" target=\"_blank\" id=\"16649119\">16649119</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12715 Version 82.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211122\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F211123\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061227\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061220\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211104\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F211090\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F12808915\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061230\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F211119\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061229\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F211145\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211144\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211110\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211094\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27778495\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299900\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222413\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F211100\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211113\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061226\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211093\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F211109\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F16319576\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4589209\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F29044095\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12715|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-drug-information\" class=\"drug drug_general\">Polyethylene glycol electrolyte solution: Drug information</a></li><li><a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-patient-drug-information\" class=\"drug drug_patient\">Polyethylene glycol electrolyte solution: Patient drug information</a></li></ul></div></div>","javascript":null}